论文部分内容阅读
自1977年6月起,我们曾试用汉防己甲素片剂(以下简称汉甲)治疗10例单纯矽肺患者。每日口服剂量为200～300mg,两个疗程服药总量分别为20.6～50.1克,及6～13.2克,共进行了一年的临年观察。观察中发现患者胸片矽肺病变稳定,血兰蛋白稍有下降,但第一疗程中普遍出现腹胀及皮肤色素沉着等副作用,两疗程中先后有4例患者出现肝功异常,同时发现汉甲排泄缓慢,停药半年后服药总量少的病人尿中已不排出汉甲,而服药总量高的病人,尿中仍可测出少量汉甲。为了进一步摸清服药及停药期间汉甲在人体内的贮留和尿中排泄的规律,为临床设计合理安全的治疗方案提供参
Since June 1977, we have tried tetrandrine tablets (hereinafter referred to as “Hanjia”) for 10 patients with silicosis alone. Daily oral dose of 200 ~ 300mg, two courses taking the total amount of 20.6 to 50.1 grams, respectively, and 6 to 13.2 grams, a total of one year of adolescent observation. Observation found that patients with chest X-ray silicosis lesions stable, slightly decreased blood albumin, but the first course of treatment generally appear abdominal distension and skin pigmentation and other side effects, two courses of treatment has occurred in 4 patients with abnormal liver function, and also found that Han excretion Slow, discontinued six months after taking less total urine in patients with urinary excretion has not excreted, while the total amount of medication in patients with high urine can still detect a small amount of Nail. In order to further find out the regularity of the retention and urinary excretion of Hannel in the human body during medication and withdrawal, and provide reference for the clinical design of a reasonable and safe treatment plan